Clinical-stage biopharmaceutical company developing precision medicines for cancer.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing cancer treatments within the United States. The company focuses on developing small molecule therapies designed to target various forms of cancer. Central to its pipeline are innovative product candidates such as ziftomenib, a small molecule inhibitor targeting the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. Ziftomenib is specifically tailored for genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia.
Additionally, Kura Oncology's lead product candidate, tipifarnib, represents an orally bioavailable inhibitor of farnesyl transferase. Currently undergoing Phase II clinical trials, tipifarnib shows promise for treating both solid tumors and hematologic indications. The company has forged a clinical collaboration with Novartis to explore the combination of tipifarnib with alpelisib in patients suffering from head and neck squamous cell carcinoma, particularly those whose tumors exhibit HRAS overexpression or PIK3CA mutation and/or amplification.
Founded in 2014 and headquartered in San Diego, California, Kura Oncology, Inc. is positioned at the forefront of oncological research and development. The company's commitment to innovation and collaboration underscores its mission to address critical unmet medical needs in cancer care through novel therapeutic approaches.
With a strong emphasis on precision medicine, Kura Oncology leverages cutting-edge scientific insights to advance transformative treatments that have the potential to significantly impact the lives of cancer patients worldwide.